Chu Limoges
Limoges, Haute Vienne, 87042, France
Location status: Recruiting
Location contact
Céline RIGAUD, MSc
CONTACT
FRANCOIS Sandrine, PhD
CONTACT
NCT Number: NCT05361603
The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program, addictology nurse and social worker) and to propose appropriate management for each situation assessed.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Limoges, Haute Vienne, 87042, France
Location status: Recruiting
Céline RIGAUD, MSc
CONTACT
FRANCOIS Sandrine, PhD
CONTACT
Each patient presenting during the screening day will have an individualized welcome.
Addictological and hepatological data will be collected throughout the process by the various workers on the individual Scanvir form (attached).
Method for routine management of patients according to results :
The patient meets directly with the hepatologist to screen for risk factors for chronic liver disease (alcohol, medications ...).
The nurse at the facility reviews with the patient the modes of transmission of the viruses and discusses with him/her risk reduction and harm reduction and what to do in case of recent exposure.
The hepatologist offers to do an immediate and on-site HCV RNA by delocalized PCR (GeneXpert). If the HCV RNA is positive, HCV treatment is started immediately (excluding comorbidity). An appointment is proposed 3 months after treatment to control the cure by delocalized PCR on site (RVS12)
The hepatologist proposes to do immediately and on site a complete blood test (HIV serology, HBV serologies (HBsAg, HBcAb, HBsAb) by the nurse present, assesses other risk factors and schedules an appointment for the results and management.
For all situations, a prevention action to reduce the risks of transmission of HCV and HBV will be carried out at the same time.
An anti-viral B vaccination may be offered.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 10 years
Evaluate the acceptability of simultaneous screening for viral hepatitis B, C and HIV among drug users in non-conventional structures using a dual method by RTDs and FibroScan®
Time frame: up to 10 years
Evaluate the acceptability of simultaneous screening for viral hepatitis B, C and HIV among drug users in non-conventional structures using a dual method by RTDs and FibroScan®
Time frame: up to 10 years
Evaluate the feasibility of simultaneous screening for viral hepatitis B, C and HIV in drug users in non-conventional structures using a dual screening method TROD and FibroScan®
Time frame: up to 10 years
Evaluate the acceptability of risk reduction methods as part of the care pathway.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Time frame: up to 10 years
Evaluate the impact of screening in terms of patient care.
Contact information is provided by the study sponsor or research team.
Marilyne DEBETTE-GRATIEN, MD
CONTACT
Véronique LOUSTAUD-RATTI, Prof
CONTACT
University Hospital, Limoges
Other
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Facilities "Outside the Walls" Using the Dual Screening Method TROD (Rapid Diagnostic Tests) and FibroScan
Acronym: SCANVIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03135886
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
New York, United States
View Trial DetailsNCT03949764
Blood-Borne Infections, Chemically-Induced Disorders
Hazard, Kentucky, United States
View Trial DetailsNCT04947475
Actinomycetales Infections, Bacterial Infections
Bishkek, Kyrgyzstan
View Trial DetailsNCT05668780
Blood-Borne Infections, Chemically-Induced Disorders
Morgantown, West Virginia, United States
View Trial Details